Results from the second WHO external quality assessment for the molecular detection of respiratory syncytial virus, 2019– 2020
Williams, Thomas; Jackson, Sandra; Barr, Ian; Bi, Shabana; Bhiman, Jinal N.; Ellis, Joanna; Von Gottberg, Anne; Lindstrom, Stephen; Peret, Teresa; Rughooputh, Sanjiv; Viegas, Mariana; Hirve, Siddhivinayak; Zambon, Maria; Zhang, Wenqing; WHO RSV Surveillance Group; MH Al-Nabet, Ajaeb Dakhilalla; Abubakar, Abdinasir; Tivane, Almiro; Barakat, Amal; Naguib, Amel; Aziz, Ammar; Vicari, Andrea; Moen, Ann; Govindakarnavar, Arunkumar; Hall, Aron; Darmaa, Badarch; Bastien, Nathalie; Herring, Belinda; Caetano, Braulia C.; Whittaker, Brett; Baumeister, Elsa; Nakoune, Emmanuel; Guthrie, Erica; Inbanathan, Francis; Nair, Harish; Campbell, Harry; Kadjo, Herve A.; Oumzil, Hicham; Heraud, Jean-Michel; Mott, Joshua A.; Namulondo, Joyce; Leite, Juliana; Nahapetyan, Karen; Al Ariqi, Lubna; Gazo, Mahmoud Hamad Ibraheem; Chadha, Mandeep; Pisareva, Maria; Venter, Marietjie; Siqueira, Marilda M.; Lumandas, Mayan; Niang, Mbayame; Albuaini, Mona; Salman, Muhammad; Dia, Ndongo; Razanazatovo, Norosoa; Oberste, Steve; Srikantiah, Padmini; Tang, Patrick; Couto, Paula; Smith, Peter; Coyle, Peter Valentine; Dussart, Philippe; Nguyen, Phuong Nam; Okada, Pilailuk Akkapaiboon; Wijesinghe, Pushpa Ranjan; Samuel, Reuben; Brown, Richard; Pebody, Richard; Fasce, Rodrigo; Jha, Runa; Lindstrom, Stephen; Gerber, Sue; Potdar, Varsha; Dong, Xiaomin; Deng, Yi Mo
Date:
2023-01
Abstract:
BACKGROUND : External quality assessments (EQAs) for the molecular detection of
human respiratory syncytial virus (RSV) are necessary to ensure the standardisation
of reliable results. The Phase II, 2019–2020 World Health Organization (WHO) RSV
EQA included 28 laboratories in 26 countries. The EQA panel evaluated performance
in the molecular detection and subtyping of RSV-A and RSV-B. This manuscript
describes the preparation, distribution, and analysis of the 2019–2020 WHO
RSV EQA.
METHODS : Panel isolates underwent whole genome sequencing and in silico primer
matching. The final panel included nine contemporary, one historical virus and two
negative controls. The EQA panel was manufactured and distributed by the UK
National External Quality Assessment Service (UK NEQAS). National laboratories
used WHO reference assays developed by the United States Centers for Disease
Control and Prevention, an RSV subtyping assay developed by the Victorian Infectious
Diseases Reference Laboratory (Australia), or other in-house or commercial
assays already in use at their laboratories.
RESULTS : An in silico analysis of isolates showed a good match to assay primer/probes.
The panel was distributed to 28 laboratories. Isolates were correctly identified in
98% of samples for detection and 99.6% for subtyping.
CONCLUSIONS : The WHO RSV EQA 2019–2020 showed that laboratories performed
at high standards. Updating the composition of RSV molecular EQAs with contemporary
strains to ensure representation of circulating strains, and ensuring primer
matching with EQA panel viruses, is advantageous in assessing diagnostic competencies
of laboratories. Ongoing EQAs are recommended because of continued evolution
of mismatches between current circulating strains and existing primer sets.
Description:
DATA AVAILABILITY STATEMENT :
Data available on request due to privacy/ethical restrictions.